publication date: Jan. 20, 2017
Issue 3 - Jan. 20, 2017
CL43-03 (308 downloads)

  • “Will I still have coverage?” patients ask oncologists as Republicans move to gut Affordable Care Act

    As Congress lays down the groundwork for dismantling the Affordable Care Act, doctors across America are hearing cancer patients speak of their fear of losing access to care if the law known as “Obamacare” is jettisoned without replacement.

  • FDA forms Oncology Center of Excellence, names Richard Pazdur director

    On his last full day as FDA commissioner, Robert Califf announced the formation of the Oncology Center of Excellence and named Richard Pazdur its director.

    The process of forming the center began in June, and Pazdur has been the acting director. Reorganization of the FDA oncology portfolio is an element of the Obama White House Moonshot Initiative.

  • Guest Editorial

    NCI formulary, moonshot and public-private partnerships

    Announcing the NCI Formulary, the Jan. 13 issue of The Cancer Letter includes comments suggesting the road to new therapies will now get “easier” and other comments indicated that industry and/or NCI collaborators will “not provide support other than drug access”.

  • In Brief

    • Richard Goldberg new director of West Virginia University Cancer Institute
    • Justin Klamerus named president of Karmanos Cancer Hospital
    • Werner-Wasik new executive vice chair, radiation oncology integration at Jefferson
    • Northwell Health partners with Indivumed to create cancer research biobank
    • Tempus and University Hospitals/Seidman announce effort to customize treatment
    • Reporting of lung cancer surgery outcomes provides info about quality of care

  • Drugs & Targets

    • Medicinal product designation for TB-403 for medulloblastoma

  • Funding Opportunities

    LUNGevity issues RFA for career development award

    LUNGevity announced a request for applications for translational research for career development awards that will be granted in 2017.

Copyright (c) 2020 The Cancer Letter Inc.

Back to top